ACE2 and TMPRSS2 expression in patients before, during, and after SARS-CoV-2 infection

Front Cell Infect Microbiol. 2024 Mar 28:14:1355809. doi: 10.3389/fcimb.2024.1355809. eCollection 2024.

Abstract

During the SARS-CoV-2 pandemic angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) were constantly under the scientific spotlight, but most studies evaluated ACE2 and TMPRSS2 expression levels in patients infected by SARS-CoV-2. Thus, this study aimed to evaluate the expression levels of both proteins before, during, and after-infection. For that, nasopharyngeal samples from 26 patients were used to measure ACE2/TMPRSS2 ex-pression via qPCR. Symptomatic patients presented lower ACE2 expression levels before and after the infection than those in asymptomatic patients; however, these levels increased during SARS-CoV-2 infection. In addition, symptomatic patients presented higher expression levels of TMPRSS2 pre-infection, which decreased in the following periods. In summary, ACE2 and TMPRSS2 expression levels are potential risk factors for the development of symptomatic COVID-19, and the presence of SARS-CoV-2 potentially modulates those levels.

Keywords: ACE2; SARS-CoV-2; TMPRSS2; host-parasite; pathogenicity.

MeSH terms

  • Angiotensin-Converting Enzyme 2* / genetics
  • COVID-19*
  • Humans
  • SARS-CoV-2
  • Serine Endopeptidases* / genetics

Substances

  • Angiotensin-Converting Enzyme 2
  • Serine Endopeptidases
  • TMPRSS2 protein, human

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by Fundação de Amparo à Pesquisa e Extensão Universitária (FAPEU) and Universidade Federal de Santa Catarina (UFSC), grant number FAPEU 4/2022.